GT Biopharma, Inc 8-K, filed Sep 23, 2021
GT Biopharma, Inc. (GTBP)
About this 8-K
GT Biopharma, Inc filed this 8-K on September 23, 2021, reporting on events of September 17, 2021.
Items reported
- Item 8.01: Other events
- Item 9.01: Financial statements and exhibits
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM
CURRENT REPORT
Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934
Date of Report:
(Date of earliest event reported)
(Exact name of registrant as specified in its charter) |
(State or other Jurisdiction of Incorporation)
| ||
(Commission File Number) |
| (IRS Employer Identification No.) |
(Address of Principal Executive Offices and zip code) |
(
(Registrant’s telephone number, including area code)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of registrant under any of the following provisions:
Securities registered pursuant to Section 12(b) of the Act:
Title of each Class |
| Trading Symbol(s) |
| Name of each Exchange on which registered |
|
| The |
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR 230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR 240.12b-2).
Emerging growth company
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 8.01. Other Events.
On September 17, 2021, Dr. Jeffrey Miller, a Professor of Medicine, University of Minnesota Medical School, Division of Hematology, Oncology and Transplantation and the Registrant’s consulting Chief Scientific Officer, presented information regarding the Registrant’s drug candidates at the European Society for Medical Oncology Congress 2021. Dr. Miller’s presentation is filed as Exhibit 99.1 and is incorporated herein by reference.
The Registrant’s updated corporate presentation as of September 20, 2021, which has been posted to the Registrant’s website, is filed as Exhibit 99.2 and is incorporated herein by reference.
Item 9.01 Financial Statements and Exhibits.
(d) | Exhibits. | ||
|
|
|
|
|
| ||
|
| GT Biopharma, Inc. Corporate Presentation as of September 20, 2021. | |
2 |
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
GT BIOPHARMA, INC. | |||
| Date: September 23, 2021 | By: | /s/ Michael Handelman | |
|
| Michael Handelman | |
| Chief Financial Officer | |||
3 |
EXHIBIT 99.1
EXHIBIT 99.2
